Pyrazolo[3,4-d]pyrimidine Compounds for Selective HER2 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HER2 inhibitors, such as Lapatinib, Afatinib, and Neratinib, while effective, often cause adverse effects due to non-selective inhibition of EGFR, leading to skin problems and gastrointestinal issues, highlighting a need for a compound that selectively targets HER2 with minimal activity against EGFR.
Innovation Solution
A novel pyrazolo[3,4-d]pyrimidine compound or its salt, featuring a specific structural formula, which exhibits strong and selective inhibitory activity against HER2, reducing adverse effects by minimizing EGFR inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If known HER2 inhibitors (Lapatinib, Afatinib, Neratinib) are used to achieve high HER2 inhibitory activity, then strong antitumor effect is obtained, but adverse effects occur due to non-selective EGFR inhibition
Solution Approach 1:
The patent applies local quality by designing a compound with specific structural features (pyrazolo[3,4-d]pyrimidine core with particular substituents) that create selective binding affinity for HER2 kinase over EGFR kinase. The molecular structure is locally optimized at the binding interface to match HER2's active site geometry and electrostatic properties, enabling selective inhibition without affecting EGFR
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as substituent types, positions, and configurations on the pyrazolo[3,4-d]pyrimidine core. By adjusting these chemical parameters, the compound achieves optimal HER2 selectivity while maintaining potent inhibitory activity, shifting the selectivity profile away from EGFR inhibition
2Reliability
If high inhibitory activity against both HER2 and EGFR is achieved, then broad kinase inhibition is obtained, but selectivity for HER2 is reduced
Solution Approach 1:
The patent applies segmentation by dividing the kinase inhibitor design into distinct functional segments: a core pyrazolo[3,4-d]pyrimidine structure for HER2 binding, and specific substituent patterns that enhance selectivity. This segmented approach allows independent optimization of potency and selectivity parameters
Data Source
AI summary
To provide a novel compound having a HER2 inhibitory effect and having a cytostatic effect. It is also intended to provide a medicament useful in the prevention and/or treatment of a disease involving HER2, particularly, cancer, on the basis of the HER2 inhibitory effect. The present invention provides a compound of formula (I) wherein X, Y, Z1, Z2, Z3, Z4, W, n, R1, R2, and R3 have meanings as defined in the present specification, or a salt thereof.